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December 11, 2012:2421–6than 6.5 mm diameter cannot be closed with the ADO II. Because
the retention discs are symmetrical, a minimum distance of 3 mm
is required between the upper margin of the VSD and the aortic
Figure 1 Membranous Septal Aneurysm With Multiple Fenestrations
See arrows, top left panel. A 0.014-inch guidewire in the pulmonary artery
(arrow, top right panel) is used to stabilize the delivery catheter during device
deployment. A significant residual shunt (stippled arrow, lower left panel) is
seen, which was closed with a second device (lower right panel). ADO II 
Amplatzer duct occluder II (St. Jude Medical, St. Paul, Minnesota).valve. The ADO II device is cheap and effective for closing
When Enthusiasm Meets Reality in Real-Lif
RDN (5). The exact proportion of patients eligible for RDN withpmVSDs. Availability of larger-sized ADO II devices might
increase its applicability, allowing percutaneous closure of a wider
range of VSDs.
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Research Correspondence
Eligibility for Renal Denervation
in Patients With Resistant Hypertensione PatientsTo the Editor: Percutaneous renal sympathetic denervation (RDN)
by radiofrequency ablation is a novel therapeutic intervention that
has been shown to decrease blood pressure (BP) significantly (1)
and persistently (2) in patients with resistant hypertension (RH).
However, the evidence supporting the use of this technique was
obtained in a single randomized controlled open trial including
106 patients (1) that has been subject to methodological criticism
(3,4). This led the European Society of Hypertension (ESH) to
release a position paper that defined strict eligibility criteria forthe only device currently available (Symplicity, Medtronic, Min-
neapolis, Minnesota) in “real-life conditions” remains unknown.
However, 36 of the 190 patients screened in the Symplicity
HTN-2 (Renal Denervation in Patients With Uncontrolled Hy-
pertension) trial (1) did not meet the BP criteria for inclusion, and
30 had a renal artery anatomy incompatible with RDN.
Therefore, we estimated the number of patients eligible for
RDN by retrospectively reviewing the computerized medical
records of all consecutive patients hospitalized for at least 1 day in
2011 at our tertiary hypertension center at a university hospital in
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December 11, 2012:2421–6Paris, France. Patients were excluded if they were18 years old or
80 years old, pregnant, or normotensive or if the in-hospital
work-up to exclude secondary hypertension was incomplete. Re-
sistant hypertension was defined according to ESH guidelines (6)
as an office systolic/diastolic BP140 and/or 90 mmHg (or130
nd/or 80 mm Hg in diabetic patients) despite treatment with at
east 3 drugs (including a diuretic) prescribed at the maximal
olerated dose. Secondary causes of hypertension were excluded,
nd compliance with treatment was checked by direct interview at
ach visit to define our cohort of patients with essential RH.
For the analysis, we considered BP values measured at the last
ollow-up visit or immediately before etiological treatment of
econdary hypertension. We applied the eligibility criteria for
DN to our cohort of patients with essential RH (5): systolic office
P 160 mm Hg (or 150 mm Hg for patients with diabetes
Patients with at least 1
hospitalization in 2011 
n = 1209 
Patients included 
n = 1034 
Patients with resistant HTN  
(office BP ≥140/90 mmHg or ≥130/80 mmHg 
if diabetic) 
n = 200 
Resistant essential HTN 
n = 87 
Severe resistant HTN 
(office systolic BP ≥160 mmHg or ≥150 mmHg 
if diabetic) 
n = 31 
Patients eligible for renal denervation 
n = 24 
Renal anatomy suitable for renal 
denervation 
n = 15 
Figure 1 Patient Screening and Selection
Diagram showing patient screening for renal denervation in accordance with a Eur
BP  blood pressure; eGFR  estimated glomerular filtration rate; HTN  hyperteellitus) despite at least 3 antihypertensive drugs, including adiuretic with out-of-office BP measurements (daytime ambulatory
or home BP) 135 and/or 85 mm Hg, estimated glomerular
filtration rate (eGFR) 45 ml/min/1.73 m2 (according to the
modification of diet in renal disease formula), and suitable renal
artery anatomy (presence of a single main renal artery 4 mm in
diameter and 20 mm in length, with no significant stenosis, no
accessory artery 3 mm in diameter, no previous renal artery
intervention, and the presence of 2 kidneys).
During the course of 2011, 3,067 patients were referred to our
department, and 1,209 of these patients were hospitalized for their
work-up, 175 of whom were excluded from the analysis on the
basis of the exclusion criteria listed in the preceding text. Of the
remaining 1,034 patients, 200 (19.3%) met the definition of RH
according to the ESH criteria. In total, 113 of these 200 patients
(56.5%) were diagnosed with secondary hypertension, leaving 87 of
Excluded cases 
(age <18 or > 80 years old ; pregnancy ; 
normotensive patients ; incomplete evaluation) 
n = 175 
Secondary form of HTN 
n = 113  
Out-of-office BP normal (<135/85 mmHg) 
n = 5 
eGFR < 45ml/min/1.73 m2 
n = 2 
Renal anatomy unsuitable for renal 
denervation 
n = 9 
Society of Hypertension position paper.opean
nsion.200 (43.5%) patients with a diagnosis of essential RH. Only 31 of
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December 11, 2012:2421–6the 87 with essential RH (35.6%) fulfilled the office systolic BP
criteria (160 mm Hg or 150 mm Hg for diabetics) for RDN;
5 of these patients had out-of-office BP 135/85 mm Hg, and 2
had an eGFR 45 ml/min/1.73 m2. Consequently, only 24
atients were eligible for RDN on both BP and eGFR criteria.
enal artery anatomy was appropriate for RDN on a computed
omography angiogram reviewed by a senior radiologist in only 15
f these 24 patients (62.5%). Therefore, only 1.5% (15 of 1,034) of
ll hypertensive patients or 17.2% (15 of 87) of the patients with
ssential RH referred to our tertiary care hypertension department
ere fully eligible for RDN (see Fig. 1). These proportions might
ven be overestimates, because: 1) spironolactone, which has
roved effective for the treatment of RH (7), was prescribed to only
of 29 patients (24.1%); and 2) compliance with treatment was
ot assessed by systematic plasma or urinary drug determinations.
Our findings demonstrate that percutaneous RDN, whether for
linical trials or specific patients, is limited to a highly selected
raction of patients with RH—even in a specialist hypertension
nit—and that a thorough diagnostic work-up is essential for
ppropriate patient selection. Moreover, the risk associated with this
nvasive procedure also depends on the careful selection of patients
ligible for RDN as well as the experience of the radiologist/
ardiologist conducting the intervention. Finally, further evaluation of
his technique is still required in large, correctly designed clinical trials,
ith ambulatory BP as the primary endpoint.
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Pathophysiologic Mechanisms
Linking Coronary Heart Disease
and Depression
We would like to congratulate Blumenthal et al. (1) for their
interesting paper recently published in the Journal in which
atients with coronary heart disease (CHD) and depression
ymptoms treated with aerobic exercise reached significantly
reater reduction in depression symptoms as compared with the
ontrol group. This reduction in depression symptoms is compa-
able to the sertraline group (1). However, some issues should be
ddressed. First, in the Results section, the authors stated that
ertraline and exercise had a null effect on flow-mediated dilationimprovement in FMD (1.5%; before treatment 2.6%, after
treatment 4.1%) (1). The association between the treated group
and improvement in depression symptoms, the autonomic nervous
system, FMD, and other markers will be assessed by a 2-sided test
(2). This test provides objective information on evaluating the
effects of interventions in clinical trials. This clinical trial confirms
a recent randomized controlled trial that sertraline improved FMD
in those CHD patients treated with 85% statins (3). The data of
this study demonstrated vascular endothelial dysfunction in CHD,
and depression symptoms might be improved beyond the effects of
statins. Nevertheless, the authors did not comment on it in the
Discussion section. Second, Blumenthal et al. (1) found that
physical activity during daily life was associated with significantly
less sympathetic nervous system activity as measured by the
standard deviation of the normal-to-normal R-R intervals as
compared with the sertraline group and the placebo group. This
beneficial effect on the autonomic nervous system does not have a
